Rosiglitazone inhibits expression and secretion of PEDF in adipose tissue and liver of male SD rats via a PPAR-γ independent mechanism

Endocrinology

Volumn 155, Issue 3, 2014, Pages 941-950

  Yang, Shumin ^a   Luo, Ting ^a   Zhou, Huang ^a   Lv, Qiong ^a   Liu, Lulu ^a   Zhang, Wenlong ^a   Gao, Rufei ^a   Chen, Shumei ^a   Xia, Wei ^a   Luo, Mei ^a   Cheng, Qingfeng ^a   Li, Qifu ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; COMPOUND C; FAT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; LIPID DIET; LIVER; LIVER CELL; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

3T3-L1 CELLS; ADIPOCYTES; ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIET, HIGH-FAT; EYE PROTEINS; GENE EXPRESSION REGULATION; GLUCOSE CLAMP TECHNIQUE; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MALE; MICE; NERVE GROWTH FACTORS; PHOSPHORYLATION; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SERPINS; THIAZOLIDINEDIONES;

EID: 84896882425     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1813     Document Type: Article

References (46)

1. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-110. (Pubitemid 351916703)
2. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;5:D3053.
3. Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557-566.
4. Al-Alem L, Southard RC, Kilgore MW, Curry TE. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. PLoS One. 2011;6:e16179.
5. Akinyeke TO, Stewart LV. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism. Cancer Biol Ther. 2011;11:1046-1058.
6. Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms. J Neurotrauma. 2011;28:983-993.
7. Ye JM, Dzamko N, Hoy AJ, Iglesias MA, Kemp B, Kraegen E. Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat- fed rats. Diabetes. 2006;55:2797-2804. (Pubitemid 44923679)
8. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010;44:87-97.
9. Chang TJ, Chen WP, Yang C, et al. Serine-385 phosphorylation of inwardly rectifying K +channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats. Diabetologia. 2009;52:1112-1121.
10. Li K, Li L, Yang M, Zong H, Liu H, Yang G. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2009;161:391-395.
11. Tishinsky JM, Ma DW, Robinson LE. Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARγ-dependent manner in human adipocytes. Obesity (Silver Spring). 2011; 19:262-268.
12. Bell C. Pigment epithelium-derived factor: a not so sympathetic regulator of insulin resistance? Exerc Sport Sci Rev. 2011;39:187-190.
13. Famulla S, Lamers D, Hartwig S, et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int J Obes (Lond). 2011;35:762-772.
14. Crowe S, Wu LE, Economou C, et al. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab. 2009;10:40-47.
15. Borg ML, Andrews ZB, Duh EJ, Zechner R, Meikle PJ, Watt MJ. Pigment epithelium-derived factor regulates lipid metabolism via adipose triglyceride lipase. Diabetes. 2011;60:1458-1466.
16. Yang S, Li Q, Zhong L, et al. Serum pigment epithelium-derived factor is elevated in women with polycystic ovary syndrome and correlates with insulin resistance. J Clin Endocrinol Metab. 2011; 96:831-836.
17. Wang M, Wang JJ, Li J, et al. Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes. Am J Physiol Endocrinol Metab. 2009; 297:E1378-E1387.
18. Thomson MJ, Williams MG, Frost SC. Development of insulin resistance in 3T3-L1 adipocytes. J Biol Chem. 1997;272:7759-7764. (Pubitemid 27137330)
19. Arsenis G, Livingston JN. Alterations in the tyrosine kinase activity of the insulin receptor produced by in vitro hyperinsulinemia. J Biol Chem. 1986;261:147-153. (Pubitemid 16144825)
20. Kim B, McLean LL, Philip SS, Feldman EL. Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. Endocrinology. 2011;152:3638-3647.
21. Liu HY, Cao SY, Hong T, Han J, Liu Z, Cao W. Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). J Biol Chem. 2009;284:27090-27100.
22. Wang L, Xu ML, Rasmussen SK, Wang MH. Vomifoliol 9-O-α- arabinofuranosyl (1→6)-β-D-glucopyranoside from the leaves of Diospyros Kaki stimulates the glucose uptake inHepG2and 3T3-L1 cells. Carbohydr Res. 2011;346:1212-1216.
23. Lanner JT, Katz A, Tavi P, et al. The role of Ca2+ influx for insulin-mediated glucose uptake in skeletal muscle. Diabetes. 2006;55: 2077-2083. (Pubitemid 44509982)
24. Tran TT, Gupta N, Goh T, et al. Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol Biomarkers Prev. 2003;12:47-56. (Pubitemid 36110157)
25. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase Cθ and alterations in the insulin signaling cascade. Diabetes. 1999;48:1270-1274. (Pubitemid 29241025)
26. Filleur S, Nelius T, de Riese W, Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem. 2009;106:769-775.
27. Sunderland KL, Tryggestad JB, Wang JJ, et al. Pigment epithelium-derived factor (PEDF) varies with body composition and insulin resistance in healthy young people. J Clin Endocrinol Metab. 2012; 97:E2114-E2118.
28. NakamuraK, Yamagishi S, Adachi H, Matsui T, Kurita Y, Imaizumi T. Serum levels of pigment epithelium-derived factor (PEDF) are an independent determinant of insulin resistance in patients with essential hypertension. Int J Cardiol. 2010;143:96-98.
29. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607. (Pubitemid 19004941)
30. Corkey BE. Diabetes: have we got it all wrong? Insulin hypersecretion and food additives: cause of obesity and diabetes? Diabetes Care. 2012;35:2432-2437.
31. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31(suppl 2):S262-S268.
32. Pories WJ, Dohm GL. Diabetes: have we got it all wrong? Hyperinsulinism as the culprit: surgery provides the evidence. Diabetes Care. 2012;35:2438-2442.
33. Flores-Riveros JR, McLenithan JC, Ezaki O, Lane MD. Insulin down-regulates expression of the insulin-responsive glucose transporter (GLUT4) gene: effects on transcription and mRNA turnover. Proc Natl Acad Sci USA. 1993;90:512-516. (Pubitemid 23028893)
34. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemis-try-Us. 2002;41:6640-6650. (Pubitemid 34547354)
35. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252. (Pubitemid 28180857)
36. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
37. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996; 15:5336-5348. (Pubitemid 26336216)
38. Ko HJ, Zhang Z, Jung DY, et al. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes. 2009;58:2536-2546.
39. Gaidhu MP, Anthony NM, Patel P, Hawke TJ, Ceddia RB. Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK. Am J Physiol Cell Physiol. 2010;298:C961-C971.
40. Kim SJ, Jung JY, Kim HW, Park T. Anti-obesity effects of Juniperus chinensis extract are associated with increased AMP-activated protein kinase expression and phosphorylation in the visceral adipose tissue of rats. Biol Pharm Bull. 2008;31:1415-1421. (Pubitemid 351930660)
41. Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006;281:8748-8755. (Pubitemid 43847980)
42. Barazzoni R, Zanetti M, Sturnega M, et al. Insulin downregulates SIRT1 and AMPK activation and is associated with changes in liver fat, but not in inflammation and mitochondrial oxidative capacity, in streptozotocin-diabetic rat. Clin Nutr. 2011;30:384-390.
43. Gamble J, Lopaschuk GD. Insulin inhibition of 5′ adenosine mono-phosphate- activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation. Metabolism. 1997;46:1270-1274. (Pubitemid 27473509)
44. Berggreen C, Gormand A, Omar B, Degerman E, Göransson O. Protein kinase B activity is required for the effects of insulin on lipid metabolism in adipocytes. Am J Physiol Endocrinol Metab. 2009; 296:E635-E646.
45. Wang B, Atherton P, Patel R, Manning G, Donnelly R. Antiangiogenic effects and transcriptional regulation of pigment epithelium-derived factor in diabetic retinopathy. Microvasc Res. 2010;80:31-36.
46. Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012; 52:381-400.